Denileukin diftitox is under clinical development by Citius Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Denileukin diftitox’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Denileukin diftitox overview
Denileukin diftitox (Ontak, Remitoro) is a recombinant DNA-derived cytotoxic protein, composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133), produced in an E. coli expression system, acts as anti-neoplastic agent. It is formulated as solution and powder for solution for intravenous and intravenous drip route of administration. Ontak is indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor. Remitoro is indicated for the treatment of relapsed or refractory Peripheral T-cell Lymphoma (PTCL) and relapsed or refractory Cutaneous T-cell Lymphoma (CTCL).
Ontak (denileukin diftitox, E7272, E7777) is under development for the treatment of mycosis fungoides [MF] or Sezary Syndrome, solid tumors including cutaneous melanoma, non-small cell lung cancer, renal cell carcinoma, endometrial cancer and epithelial ovarian cancer. The drug candidate was also under development for the treatment of cutaneous T-cell lymphoma, metastatic malignant melanoma, B-cell chronic lymphocytic leukemia (CLL), pancreatic cancer, post autologous transplantation, B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma and transformed B-cell lymphoma.
Citius Pharmaceuticals overview
Citius Pharmaceuticals (Citius) is a specialty pharmaceutical company that focuses on the development and commercialization of anti-infective products in adjunct cancer care and critical care drug products. The company’s proprietary product candidates include Mino-Lok, an antibiotic lock solution intended for the treatment of patients with catheter-related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine intended to provide anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids. Citius is headquartered in Cranford, New Jersey, the US.
For a complete picture of Denileukin diftitox’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
